Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma

[EMBO Journal] Using a variety of in vitro and in vivo techniques, researchers showed that metastatic prostate cancer cells acquire a specific Na+/Ca2+ signature required for persistent invasion.

[Molecular Cell] Investigators explored the role of minor intron-containing genes and minor spliceosome in cancer, taking prostate cancer as an exemplar.

[Nature Communications] The authors uncovered dual-phosphorylated form of sterol regulatory element-binding protein 1 (SREBF1), pY673/951-SREBF1 that acts as an androgen sensor, and dissociates from androgen receptor in androgen deficient environment, followed by nuclear translocation.